RMD (ResMed) Cyclically Adjusted FCF per Share: $6.05 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

RMD ResMed Inc RMD
90 GF Score
Price $225.36
GF Value $267.46
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is ResMed Cyclically Adjusted FCF per Share?

ResMed RMD -0.28% 90 Cyclically Adjusted FCF per Share is $6.05 as of Jun. 2026. GuruFocus rates RMD with a GF Score™ of 90/100 and a GF Value™ of $267.46 (Modestly Undervalued). The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

ResMed's adjusted free cash flow per share for the three months ended in Jun. 2026 was $2.741. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $6.05 for the trailing ten years ended in Jun. 2026.

During the past 12 months, ResMed's average Cyclically Adjusted FCF Growth Rate was 16.10% per year. During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 19.30% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 14.10% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was 13.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of ResMed was 100.00% per year. The lowest was 8.30% per year. And the median was 19.70% per year.

As of today (2026-08-13), ResMed's current stock price is $225.3622. ResMed's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2026 was $6.05. ResMed's Cyclically Adjusted Price-to-FCF of today is 37.25.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of ResMed was 91.58. The lowest was 32.28. And the median was 51.55.


ResMed  (NYSE:RMD) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

ResMed's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=225.3622/6.05
=37.25

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of ResMed was 91.58. The lowest was 32.28. And the median was 51.55.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


ResMed Cyclically Adjusted FCF per Share Related Terms


ResMed Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for ResMed's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ResMed Cyclically Adjusted FCF per Share Chart

ResMed Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25 Jun26
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.37 3.56 4.26 5.21 6.05

ResMed Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.21 5.42 5.49 5.84 6.05

RMD vs MDLN, WST, COO: Cyclically Adjusted FCF per Share Comparison

For the Medical Instruments & Supplies subindustry, ResMed's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ResMed Cyclically Adjusted Price-to-FCF vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, ResMed's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where ResMed's Cyclically Adjusted Price-to-FCF falls into.


RMD
90GF Score
ResMed Inc RMD
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ResMed Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, ResMed's adjusted Free Cash Flow per Share data for the three months ended in Jun. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=2.741/333.9520*333.9520
=2.741

Current CPI (Jun. 2026) = 333.9520.

ResMed Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201609 0.487 241.428 0.674
201612 0.725 241.432 1.003
201703 0.355 243.801 0.486
201706 0.839 244.955 1.144
201709 0.528 246.819 0.714
201712 0.794 246.524 1.076
201803 0.931 249.554 1.246
201806 0.760 251.989 1.007
201809 0.226 252.439 0.299
201812 0.755 251.233 1.004
201903 0.850 254.202 1.117
201906 0.811 256.143 1.057
201909 0.948 256.759 1.233
201912 0.289 256.974 0.376
202003 1.425 258.115 1.844
202006 2.115 257.797 2.740
202009 0.857 260.280 1.100
202012 0.900 260.474 1.154
202103 1.149 264.877 1.449
202106 1.334 271.696 1.640
202109 -0.664 274.310 -0.808
202112 1.225 278.802 1.467
202203 0.444 287.504 0.516
202206 0.320 296.311 0.361
202209 0.084 296.808 0.095
202212 0.658 296.797 0.740
202303 1.705 301.836 1.886
202306 1.346 305.109 1.473
202309 1.664 307.789 1.805
202312 1.683 306.746 1.832
202403 2.570 312.332 2.748
202406 2.804 314.175 2.981
202409 2.073 315.301 2.196
202412 1.933 315.605 2.045
202503 3.769 319.799 3.936
202506 3.434 322.561 3.555
202509 2.802 324.800 2.881
202512 2.085 324.054 2.149
202603 3.531 330.213 3.571
202606 2.741 333.952 2.741

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of $6.05 mean?
ResMed (RMD) has a Cyclically Adjusted FCF per Share of $6.05 as of Jun. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on ResMed and its competitors.
Is ResMed's Cyclically Adjusted FCF per Share too high?
ResMed's current Cyclically Adjusted FCF per Share is $6.05. Overall, ResMed has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ResMed's Cyclically Adjusted FCF per Share compare to MDLN and WST?
ResMed's Cyclically Adjusted FCF per Share of $6.05 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted FCF per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on ResMed and its competitors. ResMed's current Cyclically Adjusted FCF per Share is $6.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ResMed stock overvalued right now?
Based on GuruFocus' analysis, ResMed (RMD) is currently considered Modestly Undervalued. The stock's GF Value™ is $267.46, compared to a current price of $225.36 — trading 15.7% below its estimated fair value. The current Cyclically Adjusted FCF per Share is $6.05. ResMed's overall GF Score™ is 90/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For ResMed (RMD), the current Cyclically Adjusted FCF per Share is $6.05 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ResMed (RMD) Overvalued in 2026?

Based on GuruFocus' analysis, ResMed stock appears to be undervalued. The current stock price of $225.36 is trading 15.7% below its estimated GF Value™ of $267.46. GuruFocus considers ResMed to be Modestly Undervalued.

Key valuation signals for RMD:

  • Cyclically Adjusted FCF per Share: $6.05
  • GF Value™: $267.46 vs. price of $225.36 (15.7% below fair value)
  • GF Score™: 90/100 with 1 warning sign

No single metric tells the full story. See the RMD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


ResMed Business Description

Address 9001 Spectrum Center Boulevard, San Diego, CA, USA, 92123
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with aging populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two-thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan, and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor, and payer in the out-of-hospital setting.
90GF Score

Get the complete analysis for RMD

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$225.36
Price
$267.46
GF Value